Evolution of the Average Target: RH

Evolution of the Target Price: RH

Changes in Analyst Recommendations: RH

dd7528786507c9ed88ea4ad.VvS0W4BfLNtCVDbpfqG8IaYZC25ogcfOc4Xdco4RWLg.FLv4btImbY4MEWGHHMeFGORcPh4x9PX8IfCOH_14N9QeuI012T1FtRtnYw~3b681418b9e3bc771f51440de3009a1f
08/07 Goldman Sachs Upgrades RH to Neutral From Sell, Lifts Price Target to $155 From $86 MT
09/06 RH Q1 Unlikely to Show Business Inflection, UBS Says MT
09/06 UBS Adjusts Price Target on RH to $155 From $160, Maintains Neutral Rating MT
01/04 Guggenheim Lowers Price Target on RH to $200 From $275, Keeps Buy Rating MT
01/04 RH Facing Near-Term Challenges From Execution, Supply Chain Issues, Morgan Stanley Says MT
01/04 Morgan Stanley Lowers Price Target on RH to $240 From $275, Keeps Overweight Rating MT
20/12 JPMorgan Cuts Price Target on RH to $225 From $275, Maintains Overweight Rating MT
12/12 Stifel Downgrades RH to Hold From Buy, Adjusts Price Target to $165 From $320 MT
02/25/02 William Blair Downgrades RH to Market Perform From Outperform MT
12/25/12 Telsey Advisory Downgrades RH to Market Perform From Outperform, Adjusts Pt to $220 From $255 MT
25/25/25 RH Shares Fall After Goldman Sachs Downgrade MT
24/25/24 Goldman Sachs Downgrades RH to Sell From Neutral, Adjusts Price Target to $179 From $199 MT
05/25/05 UBS Adjusts RH Price Target to $215 From $235, Maintains Neutral Rating MT
14/25/14 BofA Securities Adjusts Price Target on RH to $172 From $144 MT
07/25/07 RH Cash Flow, Demand Guidance Eases Tariff Concerns, Wedbush Says MT
03/25/03 RH Earnings Troubles Exacerbated by Trump Tariffs, Wedbush Says; Shares Down Pre-Bell MT
03/25/03 Wedbush Adjusts RH Price Target to $250 From $350, Maintains Outperform Rating MT
03/25/03 UBS Adjusts Price Target on RH to $235 From $250, Keeps Neutral Rating MT
27/25/27 RH Could See Solid Sales, Soft Margins for Fiscal Q4, Wedbush Says MT
26/25/26 BofA Securities Cuts RH Price Target to $410 From $510, Maintains Buy Rating MT
26/25/26 Wedbush Cuts Price Target on RH to $350 From $500, Keeps Outperform Rating MT
21/25/21 UBS Adjusts Price Target on RH to $250 From $440, Keeps Neutral Rating MT
30/25/30 Goldman Sachs Upgrades RH to Neutral From Sell, Raises Price Target to $374 From $261 MT
13/25/13 Morgan Stanley Upgrades RH to Overweight From Equalweight, Raises Price Target to $530 From $435 MT
08/25/08 Barclays Upgrades RH to Overweight From Equalweight, Raises Price Target to $515 From $383 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-6.91%
+12.61%
+23.23%
+43.87%
+16.28%
+31.06%
+12.44%
-2.29%
+42.14%
Average +19.16%
Weighted average by Cap. +2.48%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
187.88USD
Average target price
169.47USD
Spread / Average Target
-9.80%
High Price Target
270.00USD
Spread / Highest target
+43.71%
Low Price Target
90.00USD
Spread / Lowest Target
-52.10%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Goldman Sachs
UBS
Guggenheim
Morgan Stanley
JPMorgan Chase
Stifel Nicolaus
William Blair & Co.
Telsey Advisory Group
BofA Securities
Wedbush
Barclays
Baird
Jefferies & Co.
BNP Paribas Exane
TD Cowen
Wells Fargo Securities
Loop Capital
Citigroup
Cowen
Gordon Haskett
J.P. Morgan Chase
Trader
Investor
Global
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
187.88USD
Average target price
169.47USD
Spread / Average Target
-9.80%

Quarterly revenue - Rate of surprise